No Data
Jiangsu Shuoshi Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Some Shareholders Feeling Restless Over Jiangsu Bioperfectus Technologies Co., Ltd.'s (SHSE:688399) P/S Ratio
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH): has not yet launched business in the field of cell therapy
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) stated on the investor interaction platform that the company is currently focused on the research and development, production, and sales of in vitro diagnostic reagents, supporting testing instruments, and other in vitro diagnostic products. It focuses on disease prevention and control (CDC) and clinical maternal and child testing, and has not yet engaged in the field of cell therapy business.
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH): has repurchased 2.07% of the shares.
On September 2, Gleonhui announced that as of September 2, 2024, Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH) has repurchased a total of 1.21066 million shares through centralized bidding trading, accounting for 2.07% of the total share capital. The highest purchase price is 79.70 yuan/share, the lowest purchase price is 69.70 yuan/share, and the total amount paid is 92.0759 million yuan (excluding stamp duty, trading commission, and other transaction fees).
Jiangsu Shuoshi Biotechnology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Shuoshi Biotechnology Co., Ltd.
No Data
No Data